There has been a recent resurgence in the importance of the diabetes and cardiovascular disease interface. Specifically, new therapies have emerged that have been shown to improve cardiovascular outcomes considerably. Among these therapies are the class of agents called SLGT2 inhibitors. In addition to reducing CV risk in general, there is particular excitement about their potential in the management of patients with heart failure. However, there remains a generally low level understanding of not only how these drugs work but also how the should be prescribed and integrated into clinical practice. This session will address these topics.
Associate Professor of Medicine,
Credits: None available.
You must be logged in and own this session in order to